GSK Pauses Development of Herpes Vaccine After Phase II Trial Fails to Show Efficacy

GSK plc has announced that its phase II data analysis for the HSV vaccine candidate, GSK3943104, from the TH HSV REC-003 trial, did not meet its primary efficacy goal. This study was designed to test the potential clinical benefits of the early-stage herpes simplex virus vaccine. As a result, the vaccine candidate will not move forward to phase III trials. However, no safety concerns were found during the trial.

While GSK will continue monitoring for routine safety and follow-up data to better understand recurrent genital herpes, the company remains committed to innovation in this space. GSK aims to review all collected data to guide future research and the development of its herpes simplex virus program. The need for novel solutions to manage genital herpes remains a priority for the company.